Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy

Overview of attention for article published in Journal of Clinical Investigation, February 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter: 38 X users

patent: 3 patents

Readers on

mendeley: 122 Mendeley

So far, Altmetric has seen 42 X posts from 38 X users, with an upper bound of 127,559 followers.

Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy https://t.co/O82i2W61Ma

Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. https://t.co/Vr0O5SS4vR

RT @AnandRotte: Study published @jclinicalinvest finds nonpersistent #cancervaccine formulations based on dendritic cells, viral vectors, o…

Study published @jclinicalinvest finds nonpersistent #cancervaccine formulations based on dendritic cells, viral vectors, or water-soluble peptides synergized with #CheckpointBlockers #CTLA4 #PDL1 & induced complete tumor regression #immunotherapy h…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 38 additional X posts.